NEWS & RESOURCES

Altesa Biosciences Secures $75 Million Series B Following Positive Phase 2a Rhinovirus Challenge Study in COPD

Altesa Biosciences Secures $75 Million Series B Following Positive Phase 2a Rhinovirus Challenge Study in COPD

27 Feb 2026 |

Learn More

St Mary’s Hospital Questionnaire

11 Dec 2025 |

Learn More
St Mary’s Hospital Clinical Trial Questionnaire

St Mary’s Hospital Clinical Trial Questionnaire

6 Dec 2025 |

Learn More
Vapendavir for rhinovirus-triggered COPD exacerbations: phase 2a study results

Vapendavir for rhinovirus-triggered COPD exacerbations: phase 2a study results

16 Oct 2025 |

Learn More
Results from the VirTus Respiratory Research Ltd Human Rhinovirus Challenge Model Used to Advance Altesa BioSciences’ Lead Medicine into Advanced Clinical Trials

Results from the VirTus Respiratory Research Ltd Human Rhinovirus Challenge Model Used to Advance Altesa BioSciences’ Lead Medicine into Advanced Clinical Trials

2 Jul 2025 |

Learn More
Bronchial mucosal IFN-α/β and pattern recognition receptor expression in patients with experimental rhinovirus-induced asthma exacerbations.

Bronchial mucosal IFN-α/β and pattern recognition receptor expression in patients with experimental rhinovirus-induced asthma exacerbations.

6 Dec 2019 |

Learn More
Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation.

Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation.

6 Dec 2019 |

Learn More
Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations.

Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations.

6 Nov 2019 |

Learn More
Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production.

Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production.

3 Nov 2019 |

Learn More
Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation.

Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation.

3 Nov 2019 |

Learn More
Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease.

Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease.

3 Nov 2019 |

Learn More
Oxidative and nitrosative stress and histone deacetylase-2 activity in exacerbations of COPD.

Oxidative and nitrosative stress and histone deacetylase-2 activity in exacerbations of COPD.

3 Nov 2019 |

Learn More
Mucosal type 2 innate lymphoid cells are a key component of the allergic response to aeroallergens.

Mucosal type 2 innate lymphoid cells are a key component of the allergic response to aeroallergens.

3 Nov 2019 |

Learn More
IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo.

IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo.

18 Sep 2019 |

Learn More
Role of deficient type III interferon-lambda production in asthma exacerbations.

Role of deficient type III interferon-lambda production in asthma exacerbations.

18 Sep 2019 |

Learn More